胞磷胆碱(Citicoline) - 在研适应症：胰腺炎，意识障碍，帕金森病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

CDP-choline、Citicoline (JP17/INN)、NSC-122002

+ [6]

靶点-

作用方式-

作用机制-

治疗领域

神经系统疾病消化系统疾病内分泌与代谢疾病+ [1]

在研适应症

胰腺炎意识障碍帕金森病

非在研适应症

急性缺血性卒中大脑中动脉梗塞

原研机构

Takeda Pharmaceutical Co., Ltd.

在研机构

T’s Pharma Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

非在研机构

Ferrer Internacional SA

权益机构

Grupo Ferrer Internacional SA

Acino International AG

最高研发阶段批准上市

首次获批日期

日本 (1976-02-10),

帕金森病

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C14H26N4O11P2

InChIKeyRZZPDXZPRHQOCG-OJAKKHQRSA-N

CAS号987-78-0

关联

63

项与胞磷胆碱相关的临床试验

IRCT20251105067890N1

/ Recruiting临床2期IIT

Effect of Citicoline on the Cognitive Status and Functional Prognosis of Patients with Traumatic Brain Injury

开始日期2025-11-22

申办/合作机构

Tabriz University of Medical Sciences

IRCT20241029063537N2

/ Suspended临床4期IIT

Investigating the effect of citicoline administration on cognitive impairment, social interactions, and speech status in autistic children at pre-school and post-school ages

开始日期2025-07-23

申办/合作机构

Semnan University of Medical Sciences

IRCT20171116037503N3

/ Suspended临床3期

Evaluating the effect of Citicoline on development of preterm infants with intraventricular hemorrhage admitted in neonatal intensive care units

开始日期2024-10-22

申办/合作机构

Shiraz University of Medical Sciences

100 项与胞磷胆碱相关的临床结果

登录后查看更多信息

100 项与胞磷胆碱相关的转化医学

登录后查看更多信息

100 项与胞磷胆碱相关的专利（医药）

登录后查看更多信息

1,471

项与胞磷胆碱相关的文献（医药）

2026-01-01·METABOLIC ENGINEERING

Systematic rewiring of Bacillus subtilis for efficient de novo biosynthesis of the neuroprotectant cytidine-5′-diphosphocholine

Article

作者: Feng, Xu ; Gao, Xiuzhen ; Ma, Qinyuan ; Wang, Yanshuang ; Yang, Shaomei ; Wei, Hao ; Fu, Shouying

Cytidine-5'-diphosphocholine (CDP-choline) is a crucial neuroprotective agent. Current industrial production relies on chemical and enzymatic methods that face inherent sustainability challenges and share a dependence on the costly precursor, cytidine monophosphate (CMP). Here, we report the systems metabolic engineering of Bacillus subtilis for the efficient, de novo biosynthesis of CDP-choline from glucose, completely obviating the need for CMP. A synthetic pathway was first established by introducing heterologous choline kinase and phosphocholine cytidylyltransferase. Subsequently, a multi-module engineering strategy was implemented, focusing on enhancing precursor supply and redirecting carbon metabolism. This involved systematically optimizing choline uptake by overexpressing the transporter OpuD and deleting the transcriptional repressor opcR, fortifying the cytidine triphosphate (CTP) pool by overexpressing feedback-resistant CTP synthase gene pyrG^E156K, and deleting the transcriptional repressor pyrR along with other pyrimidine nucleotide consumption genes, and channeling carbon flux towards the TCA cycle by reducing pyruvate and malate consumption. The final engineered strain achieved a titer of 4.79 ± 0.24 g/L CDP-choline in a 5 L fed-batch bioreactor, with a high specific yield of 149.0 ± 5.8 mg/g DCW. Notably, the process exhibited a highly advantageous intracellular accumulation of 92.7 %, which simplifies downstream purification. This study represents the first successful demonstration of CDP-choline production from simple sugars in a microbial host, establishing a robust and economically competitive platform for its industrial manufacture.

2026-01-01·JOURNAL OF NEUROTRAUMA

Citicoline–Amantadine Trial in Traumatic Brain Injury: A Prospective Randomized Study

Article

作者: Fathy, Mai ; Badre, Dina Salah Eldin Mahmoud ; Elbeialy, Marwa Ahmed Khairy

Traumatic brain injury (TBI) is a global health problem. Amantadine and citicoline showed considerable effects on neurorecovery from TBI. In a randomized controlled trial, the effects of amantadine and citicoline and their combinations were compared on arousal and behavioral consequences in the early phase of moderate TBI. Patients were divided into three groups (15 patients each) with moderate TBI; group C (citicoline) received 1 g citicoline every 12 h for 7 days. Participants received 500 mg oral drops syrup twice a day or the same dose as oral drops syrup of citicoline through a nasogastric tube (NG) or percutaneous endoscopic gastrostomy (PEG) tube in a total dose of 1000 mg/day for a 30-day study period. Group A (amantadine) received 200 mg of amantadine sulfate in a 500 mL solution every 12 h for 7 days. Participants received two 100-mg tablets twice a day or through an NG or PEG tube as 400 mg for a 30-day study period. Group CA (Citicoline + Amantadine) received 1 g citicoline every 12 h and 200 mg of amantadine sulfate in a 500 mL solution every 12 h for 7 days, then 500 mg of citicoline syrup twice daily plus 200 tablets twice daily amantadine for a 30-day study period. Glasgow Coma Scale (GCS), Disability Rating Scale (DRS), and mini-mental state (MMS) were used to assess the patient’s conditions on the 1st, 4th, and 7th days (acute phase) in the intensive care unit (ICU), then 30 days after injury. The endpoints of the study were either the death of the patient or the completion of the study period of 30 days. The number of mechanically ventilated patients, the number of ventilated days, mortality, total ICU, and hospital length of stay were measured. GCS on days 4, 7, and 30 were significantly higher in group A and group CA compared with group C, with no significant differences between groups A and CA. DRS in days 4 and 7 became significantly lower in groups A and CA compared with group C, with no significant differences between groups A and CA. MMS in days 4, 7, and 30 became significantly lower in group C, with no significant differences between groups A and CA. The duration of mechanical ventilation, ICU, and hospital stay was significantly longer in group C, with no significant differences between groups A and CA. This study showed that amantadine alone or in combination with citicoline has a favorable effect on the recovery of consciousness and cognitive behavior in patients with moderate TBI and reduces the mechanical ventilation days, hospital, and ICU length of stay.

2025-12-01·Cell Reports

SLC44A1 deficiency impedes myelin development in the central nervous system

Article

作者: Chen, Qiang ; Li, Zhenghao ; Liu, Peng ; Qiu, Mengsheng ; Su, Zhida ; He, Cheng ; Chen, Xiang ; Shao, Qi ; Zhou, Wenhao ; Huang, Hao

The axon-wrapping myelin sheath is essential for CNS function. Myelination defects occur in various neurodevelopmental disorders, but the underlying mechanism remains poorly understood. Human solute carrier 44A1 (SLC44A1) deficiency causes a new type of childhood-onset neurodegeneration with cerebellar atrophy and leukoencephalopathy that lacks effective treatment. Here, we show that SLC44A1 is enriched in oligodendrocytes and is required for myelin development in the CNS of zebrafish and rodents. In vivo time-lapse imaging of Slc44a1b-deficient zebrafish reveals impaired oligodendroglial maturation and myelinogenesis. Mechanistically, SLC44A1 deficiency disrupts the expression of genes involved in the phosphatidylcholine production pathway and subsequently inhibits phospholipid biosynthesis and disturbs the lipid composition of myelin sheaths. More importantly, supplementation with citicoline, a natural choline metabolite, restores developmental myelination in SLC44A1-deficient animals. Our findings demonstrate that SLC44A1 is essential for CNS myelination, and citicoline supplementation represents a potential therapy for developmental hypomyelination.

56

项与胞磷胆碱相关的新闻（医药）

2026-02-18

·PRNewswire

Kyowa Hakko Clarifies Glutathione Misconceptions with Science-Backed Insights on Quality and Efficacy of its Industry-Leading Setria® Brand

Setria® Glutathione - the 20-year, worldwide trusted standard: human clinical research on oral uptake gets it noticed, and brand equity keeps it chosen NEW YORK, Feb. 18, 2026 /PRNewswire/ -- As glutathione gains visibility in health and wellness, questions have followed about quality, substantiation, and whether oral glutathione can meaningfully impact glutathione inside the body's cells. Kyowa Hakko Bio, producer of Setria® Glutathione, provides guidance to dispel myths, emphasize evidence-based benefits, and set the standard for this "master antioxidant." Continue Reading Setria Logo Setria® was introduced nearly two decades ago to bring verified quality and documentation to a category that often varies widely in purity and substantiation. Glutathione plays a vital role in cellular defense, detoxification, and immune support. It's now mainstream, but market growth has led to variability, ranging from high-quality, clinically studied forms to unverified products with exaggerated claims. Meanwhile, NHANES (the National Health and Nutrition Examination Survey) data suggest that much of the population is deficient in glutathione, likely due to modern diets that often lack glutathione-rich foods, making it more important than ever to address this widespread deficiency and support optimal health with Setria® Glutathione. "The key isn't if glutathione matters, but whether oral forms can deliver real results," said Katie Emerson, MS, RD, Senior Manager of Scientific Affairs at Kyowa Hakko USA. "The Richie et al. study provides the first direct evidence that orally administered glutathione is absorbed into the systemic circulation, helping to address longstanding skepticism regarding the bioavailability of oral glutathione." Setria® glutathione stands out with unmatched clinical backing. A six-month Penn State study, published in the European Journal of Nutrition, showed that daily doses of 250 mg or 1,000 mg increased glutathione levels by 30-35% in blood cells and 260% in buccal cells, with functional benefits including a doubling of natural killer cell activity. Setria goes beyond basic antioxidant support. Research shows it supports skin health, with a 12-week study demonstrating reductions in melanin. In sports nutrition, studies indicate that when combined with L-citrulline, Setria helps increase nitric oxide to support performance, as reviewed in the Journal of Exercise and Nutrition. These benefits align with permitted structure/function claims related to cellular and mitochondrial health, antioxidant defense, immune support, skin health, liver health, gut health, respiratory health, and nitric oxide function. Manufactured via a proprietary fermentation process, Setria® meets USP standards, is GMP-compliant, and is IGEN-certified, ensuring purity amid the risks posed by low-cost alternatives. While endogenous glutathione production through diet and lifestyle is primary, supplementation can aid when levels dip due to age or stress. "Supplementation complements, not replaces, foundational health practices," Emerson said. "Its results are supported by human clinical data and produced to consistent quality standards that partners have trusted for nearly two decades." Setria® Glutathione is a globally market-ready dietary ingredient, with broad acceptance for use in supplement formulations across key regions. It can be sold as a dietary ingredient in the United States, Canada, Mexico, and Brazil, as well as throughout Europe, Southeast Asia, Australia, and New Zealand—making it an ideal option for brands looking to support consistent product positioning and international expansion. In Brazil, Setria® stands apart as the only source of glutathione approved by ANVISA (the Brazilian Health Regulatory Agency). As regulations tighten, stakeholders must prioritize substantiated claims. Kyowa Hakko promotes evidence-based choices to foster trust in glutathione's potential for immune, skin, and overall aging support. — Setria® — About Setria: Setria® Glutathione, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and patented form of glutathione that, when taken orally, has been shown to replenish the body's reserves, which may be depleted as a result of poor lifestyle choices, stress, or natural aging. Called the "master antioxidant," glutathione helps protect cells in the body from the damaging effects of oxidative stress and toxins. Setria® Glutathione is manufactured through a patented fermentation process to yield high purity and high quality, is non-GMO, vegetarian, and allergen-free. For more information, visit . About Kyowa Hakko USA: Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co., Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including Cognizin®, Eyemuse® Lacticaseibacillus paracasei KW3110, Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit . SOURCE Kyowa Hakko U.S.A 21% more press release views with Request a Demo

上市批准临床结果

2026-02-14

·补剂前沿

通路革新：胞磷胆碱经肠道靶向调节，为大脑健康提供新策略，推动认知健康机制升级

近日，日本麒麟控股有限公司与富士通有限公司联合宣布，双方通过运用创新性的“药物发现DX”技术，结合人工智能深度分析与实验验证，在全球范围内首次成功揭示了胞磷胆碱作用于肠脑轴的全新作用机制。本次研究发现源于麒麟与富士通联合推进的食品功能模拟研究计划，该计划旨在探索并开发食品的新功能属性。研究采用定量系统药理学（QSP）模型[1]，这是一种基于人工智能的数字化转型（DX）技术，常用于药物研发领域[2]，并在此基础上结合了实际实验验证。研究结果首次在全球范围内揭示了一种此前未知的脑肠轴作用机制，该机制与胞磷胆碱[3]密切相关。胞磷胆碱是人体内天然存在的一种内源性核苷，是细胞膜磷脂生物合成关键途径的中间体。神经细胞膜的修复过程需要大量胞磷胆碱参与，补充外源性胞磷胆碱可有效促进神经细胞膜磷脂的合成。胞磷胆碱在维持多种细胞生理功能中具有重要作用，对于因缺血、出血等引起的细胞膜功能障碍及相关退行性病变，胞磷胆碱已显示出明确的临床治疗效果。富士通首先基于麒麟公司的专有数据及相关文献，系统收集了胞磷胆碱的代谢谱及其作用靶点的受体信息。随后，研究团队运用数字化转型（DX）技术，构建了一套定量系统药理学（QSP）模型，用以评估胞磷胆碱的功能特性。基于该模型的模拟分析预测：口服胞磷胆碱能够增强肠-神经轴中的胆碱能信号传导（图1），并可诱导肠道突触内的乙酰胆碱水平呈现剂量依赖性升高（图2）。同时，体外实验验证进一步证实：在肠上皮细胞与神经元的共培养体系中，胞磷胆碱能够通过肠道通路有效激活神经元的信号传导（图3）。肠-脑轴作为神经科学与肠道生理学交叉领域的核心概念，阐述了肠道如何通过神经、内分泌和免疫途径影响中枢神经系统，已被广泛认为与认知功能、情绪调控以及神经退行性疾病（如阿尔茨海默病）的发生发展密切相关。先前已有临床证据表明，胞磷胆碱可促进磷脂酰胆碱合成，从而改善记忆和注意力。富士通的这项最新研究首次揭示，胞磷胆碱能够激活肠道神经元中的胆碱能受体，促使肠道突触内乙酰胆碱水平升高。此外，研究通过类器官共培养模型证实，这一通路最终可影响中枢神经系统，从而提供了外源营养素通过肠道介导来调控大脑功能的重要证据。这不仅拓展了胞磷胆碱的药理与生理作用谱，也为阐释肠-脑轴中“外周-中枢”信号传导机制提供了新的理论视角。

2026-01-22

·PRNewswire

COGNIZIN® CITICOLINE NAMED "FUNCTIONAL INGREDIENT TO WATCH IN 2026" BY MINTEL & BLACK SWAN DATA, SHOWCASING ITS EXPLOSIVE GROWTH IN THE BRAIN HEALTH CATEGORY

Independent recognition underscores Cognizin®'s role as a science‑backed leader in cognitive performance NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Kyowa Hakko USA today announced that Cognizin® (citicoline), the branded form of citicoline manufactured by Kyowa Hakko Bio Co., has been recognized as a leading "Functional Ingredient to Watch in 2026" by global market intelligence firm Mintel and consumer analytics leader Black Swan Data. This third‑party validation highlights Cognizin®'s position at the center of the rapidly growing brain health and mental performance market. Continue Reading Cognizin Logo According to the Mintel/Black Swan analysis, 65% of global product launches featuring Cognizin® include a brain or nervous system benefit, signaling strong and accelerating demand for evidence‑based cognitive support. Cognizin® now appears across a wide range of formats, from gummies and lollipops to energy drinks and advanced supplements, making it one of the most versatile and exciting ingredients in the field of functional nutrition today. "Being named an ingredient to watch in 2026 is more than a nice headline; it confirms what formulators and consumers are already telling us," said Katie Emerson, MS, RD, Senior Manager, Scientific Affairs at Kyowa Hakko USA. "Cognizin® isn't just another nootropic on a crowded shelf. It is a clinically researched, rigorously manufactured ingredient that brands are building entire product stories around. This recognition validates years of investment in science and quality and marks the beginning of Cognizin®'s mainstream breakout." Data behind the recognition The Mintel/Black Swan work highlights several key trends shaping Cognizin®'s trajectory: Strong brain‑health focus: 65% of global Cognizin® launches carry a brain or nervous system claim, making cognitive support the dominant positioning for the ingredient. Growing geographic footprint: Most launches are currently concentrated in North America (49%) and Europe (34%), indicating both strong adoption and substantial opportunities for growth in other regions. Diverse product formats: Cognizin® primarily appears in nutrition drinks (36%), energy drinks (32%), and supplements (23%), as well as emerging formats such as functional confections and beauty-from-within products. Recent launches featuring Cognizin® include science-backed products, such as Qunol, BUM Energy, MOSH, and Magic Mind, which showcase how brands use Cognizin® to deliver benefits in everyday settings. "Seeing Cognizin® across a wide range of formats underscores its versatility and impact," Emerson added. "It tells us cognitive support is no longer niche but has become a baseline expectation." Why Cognizin® stands out in a crowded nootropics landscape Cognizin® is a branded form of citicoline, a nutrient that supports the production of phosphatidylcholine, a key component of brain cell membranes and a critical player in brain cell energy. Unlike many generic nootropics, Cognizin® is backed by a substantial research portfolio. Key differentiators include: Clinical evidence: Studies have demonstrated that citicoline can support attention, memory, and cognitive performance, including MRI-based research that shows changes in brain activity. Brain energy support studies indicate citicoline can increase brain ATP (cellular energy) by approximately 13%, directly supporting mental energy and focus. Non-stimulant profile: Cognizin® delivers cognitive benefits without relying on caffeine or harsh stimulants, making it an attractive option for consumers. Quality and consistency: Produced by Kyowa Hakko using proprietary fermentation technology and strict quality controls, Cognizin® offers consistent purity and traceability for brands and consumers. "In an era where consumers are increasingly skeptical of vague 'brain boosting' claims, Cognizin®'s science‑first story matters," Emerson said. "Brands want ingredients that can stand up to evaluation from highly informed shoppers, and Cognizin does exactly that." The recognition also comes at a moment when mental performance and burnout are front‑page topics. Recent workplace and health research shows that employees and consumers are struggling with focus, attention, and mental fatigue. "2026 is shaping up to be the year people stop accepting mediocre process and scattered thoughts as the new normal," Emerson said. "They are looking for practical, daily tools that help them show up sharp—at work, in the gym, and at home. Cognizin® gives formulators a scientifically grounded way to build those solutions." Supporting innovator brands worldwide The "Functional Ingredient to Watch in 2026" designation is already inspiring new collaborations and product concepts across beverages, supplements, and functional foods. Kyowa Hakko USA is expanding its support for partners through: Formulation guidance for beverages, powders, gummies, and novel formats Science‑based marketing assets translating complex research into clear consumer language Co‑marketing opportunities spotlighting brands that formulate with Cognizin® Education initiatives for healthcare professionals, retailers, and formulators "Some of the most exciting innovations we're seeing right now are coming from brands that understand that cognitive performance is the new energy," Emerson said. "Those brands are choosing Cognizin® because they want their products to be future‑proof and aligned with where the market is going, not where it's been." — Cognizin® — About Kyowa Hakko USA Kyowa Hakko USA is a subsidiary of Kyowa Hakko Bio Co., Ltd., a global biotechnology company with over 75 years of expertise in fermentation, purification, and modification of bioactive substances. Kyowa Hakko Bio is dedicated to improving the health and well-being of people worldwide by creating innovative solutions with science and nature. With cutting-edge research capabilities, Kyowa Hakko Bio is committed to developing unique ingredients supported by scientific evidence. For more information, visit kyowa-usa.com. About Cognizin® Cognizin® Citicoline, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and branded form of citicoline, a natural substance made endogenously in the body and especially vital to brain health. Citicoline is a potent brain-health nutrient. A proprietary form of citicoline, Cognizin® has been clinically studied to support mental energy, focus, and attention. Cognizin® is manufactured through a fermentation process to yield high quality and high purity. Cognizin® is also highly stable, GRAS, ultra-pure, and allergen-free. Cognizin® can be sold as a dietary ingredient for supplements, foods, and beverages in the United States and is approved as a novel food ingredient in the EU for food supplements. For more information on Cognizin®, visit Cognizin.com. SOURCE Kyowa Hakko U.S.A 21% more press release views with Request a Demo

100 项与胞磷胆碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00057	胞磷胆碱	N06BX06	DB12153

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
胰腺炎	日本	T’s Pharma Co., Ltd.	1983-11-15
胰腺炎	日本	Takeda Pharmaceutical Co., Ltd.	1983-11-15
意识障碍	日本	T’s Pharma Co., Ltd.	1981-09-01
意识障碍	日本	Takeda Pharmaceutical Co., Ltd.	1981-09-01
帕金森病	日本	T’s Pharma Co., Ltd.	1976-02-10
帕金森病	日本	Takeda Pharmaceutical Co., Ltd.	1976-02-10

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性缺血性卒中	临床3期	德国	Ferrer Internacional SA	2006-10-01
急性缺血性卒中	临床3期	葡萄牙	Ferrer Internacional SA	2006-10-01
急性缺血性卒中	临床3期	西班牙	Ferrer Internacional SA	2006-10-01
大脑中动脉梗塞	临床3期	德国	Ferrer Internacional SA	2006-10-01
大脑中动脉梗塞	临床3期	葡萄牙	Ferrer Internacional SA	2006-10-01
大脑中动脉梗塞	临床3期	西班牙	Ferrer Internacional SA	2006-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02582905 (CTgov)	临床4期	躁郁症 \| 酒精使用障碍 \| 躁郁症2型 ... 更多	96	Placebo (Placebo)	蓋夢憲鹹構鏇夢獵繭鏇(艱構窪淵淵憲壓淵積築) = 餘獵鬱積廠憲築襯憲廠蓋築糧齋衊選鬱遞鹽憲 (糧鹹構選觸觸觸構獵壓, 4.68) 更多	-	2024-10-09
				Citicoline (Citicoline)	蓋夢憲鹹構鏇夢獵繭鏇(艱構窪淵淵憲壓淵積築) = 艱憲憲網遞觸構窪憲築蓋築糧齋衊選鬱遞鹽憲 (糧鹹構選觸觸觸構獵壓, 3.84) 更多
NCT01502813 (CTgov)	N/A	认知	40	Omega-3 Fatty Acids+Creatine+Citicoline	餘醖餘襯製鹽窪積衊構(願鏇製醖構蓋製鹽築選) = 鹹糧夢餘膚簾衊夢夢網齋繭構壓膚餘廠蓋糧鹹 (糧壓糧淵繭膚選鏇構齋, 齋齋醖鹹遞鏇積壓繭獵 ~ 網鹽鑰鬱蓋獵衊壓淵製) 更多	-	2021-04-22
NCT02074735 (CTgov)	临床4期	酗酒	62	Placebo (Placebo)	繭網築顧製廠網艱夢餘(鑰鹹鑰餘網鏇鹽膚鏇糧) = 遞餘糧憲鹹廠齋鹽淵鏇獵網蓋網選廠顧範遞襯 (艱蓋鏇觸淵糧遞觸鬱鬱, 0.30) 更多	-	2018-07-24
				Citicoline (Citicoline)	繭網築顧製廠網艱夢餘(鑰鹹鑰餘網鏇鹽膚鏇糧) = 壓淵衊淵鏇構範獵餘遞獵網蓋網選廠顧範遞襯 (艱蓋鏇觸淵糧遞觸鬱鬱, 0.38) 更多
NCT00619723 (CTgov)	临床4期	可卡因相关疾病 \| 躁郁症1型	130	Cognitive Behavioral Therapy (CBT)+Citicoline (Citicoline)	築網簾積膚獵鑰鬱鹽繭 = 鏇鏇範鹽構願築獵網艱構衊製鹹網鹽獵醖膚鬱 (遞鹹壓簾鏇蓋夢觸鹽窪, 製網鑰製顧選鏇襯鹹網 ~ 選壓壓淵壓範願構糧製) 更多	-	2018-01-24
				Placebo (Placebo)	築網簾積膚獵鑰鬱鹽繭 = 憲顧鬱選獵構壓蓋鏇衊構衊製鹹網鹽獵醖膚鬱 (遞鹹壓簾鏇蓋夢觸鹽窪, 觸窪艱鹹範範醖襯衊醖 ~ 遞憲選蓋廠壓膚醖鹽網) 更多
NCT00950352 (CTgov)	临床3期	甲基苯丙胺依赖	104	Citicoline (Citicoline)	壓願簾鏇獵壓構遞積鬱(網積鑰夢憲構顧壓製壓) = 製衊簾衊壓簾繭製獵製膚餘鏇鬱築廠鏇憲鬱糧 (齋顧鹽鑰膚夢獵糧簾壓, 0.16498) 更多	-	2015-02-11
				Placebo (Placebo)	壓願簾鏇獵壓構遞積鬱(網積鑰夢憲構顧壓製壓) = 齋獵廠膚醖鹽簾醖鬱衊膚餘鏇鬱築廠鏇憲鬱糧 (齋顧鹽鑰膚夢獵糧簾壓, 0.34547) 更多
NCT00158249 (CTgov)	临床2期	大麻滥用	21	placebo (Placebo)	積鏇淵積簾繭憲鬱夢廠(鑰鹽網積範積壓夢餘鹹) = 糧範夢鑰觸鏇衊齋鹹獵製壓鹹鏇網網鏇廠鹹積 (鏇憲鏇窪願淵鹽衊衊糧, .71) 更多	-	2014-10-22
				citicoline (Citicoline)	積鏇淵積簾繭憲鬱夢廠(鑰鹽網積範積壓夢餘鹹) = 鏇壓獵蓋願獵廠衊顧淵製壓鹹鏇網網鏇廠鹹積 (鏇憲鏇窪願淵鹽衊衊糧, 1.1) 更多
NCT00223236 (CTgov)	临床3期	可卡因相关疾病 \| 躁狂	44	Citicoline (Citicoline)	淵鹽構憲鏇襯膚夢鹽簾 = 鑰選醖鹹繭鏇膚鏇齋艱衊鏇鏇鏇淵遞淵醖顧願 (鹹窪築蓋願憲獵鏇廠範, 廠憲鬱繭願製顧醖齋築 ~ 壓膚簾蓋鬱繭廠鏇顧網) 更多	-	2014-08-11
				Placebo (Placebo)	淵鹽構憲鏇襯膚夢鹽簾 = 壓蓋積廠構鏇築顧窪簾衊鏇鏇鏇淵遞淵醖顧願 (鹹窪築蓋願憲獵鏇廠範, 衊糧醖壓壓願觸築鹽夢 ~ 築鹽鏇鹽淵構壓顧願簾) 更多
NCT00377299 (CTgov)	N/A	躁郁症 \| 重度抑郁症 \| 兴奋剂滥用 ... 更多	60	Citicoline (Citicoline)	衊鹽獵顧糧鑰窪廠範衊(遞積願醖選膚糧鏇鬱憲) = 顧範觸繭獵選糧淵淵齋遞膚顧製廠憲憲壓蓋鏇 (鬱遞顧築餘鑰襯壓顧淵, 2.5) 更多	-	2013-08-08
				Placebo (Placebo)	衊鹽獵顧糧鑰窪廠範衊(遞積願醖選膚糧鏇鬱憲) = 窪選蓋糧艱淵築憲築鹹遞膚顧製廠憲憲壓蓋鏇 (鬱遞顧築餘鑰襯壓顧淵, 3.0) 更多
NCT00545662 (COBRIT, CTgov)	临床3期	创伤性脑损伤	1,213	placebo (Control)	憲艱製積窪糧製顧襯蓋 = 鏇觸觸餘膚選鬱製繭鹹壓餘膚襯餘廠網網窪製 (積糧鹽選網鹹範壓壓齋, 壓選獵蓋簾醖積構醖憲 ~ 壓鏇衊窪齋觸製鏇積壓) 更多	-	2012-12-19
				citicoline (Treatment)	憲艱製積窪糧製顧襯蓋 = 齋齋選網糧遞選醖鏇簾壓餘膚襯餘廠網網窪製 (積糧鹽選網鹹範壓壓齋, 膚築糧鹹製夢鑰願鹹鑰 ~ 鹽餘願壓遞築鹽願夢鹽) 更多